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Abstract  9 
 10 
Lower urinary tract symptoms (LUTS) in aging men are extremely common. They have historically been 11 
attributed to benign prostatic hyperplasia (BPH), enlargement of the prostate and bladder outlet 12 
obstruction.  However, recent studies have revealed acute and chronic inflammation to by highly 13 
associated with LUTS, correlated with prostatic enlargement and implicated prostate fibrosis as a 14 
contributing cause of bladder outlet obstruction.  This review examines the evidence implicating 15 
inflammation and fibrosis in BPH/LUTS. It identifies potential mechanisms by which inflammation may 16 
drive nociceptive signaling as well as hyperplastic growth and fibrosis and identifies targets for 17 
pharmacologic intervention. This is a promising area for research and development of novel therapies 18 
to prevent or more effectively treat LUTS in aging men. 19 
  20 
Background: Lower urinary tract symptoms (LUTS) are common in aging men and include obstructive 21 
symptoms such as weak urinary stream, straining to void, and a sense of incomplete emptying as well 22 
as irritative symptoms such as frequency, urgency, nocturia.  These symptoms have generally been 23 
attributed to prostatic enlargement and an increase in outlet resistance with secondary effects on 24 
bladder function. Benign prostatic hyperplasia (BPH) is an age-related, androgen-dependent 25 
progressive enlargement of the prostate gland resulting from a non-malignant proliferative process that 26 
includes both epithelial and stromal elements.   A contribution of prostatic enlargement to development 27 
of LUTS is unequivocal. However, recent studies have shown that development of LUTS is multi-28 
factorial. Changes in smooth muscle tone in the prostate and bladder neck may increase outlet 29 
resistance independent of significant enlargement (Nickel, 1999). Age-related decrease in detrusor 30 
contractility and primary detrusor over-activity contribute significantly to lower urinary tract symptoms.  31 
Recently, prostatic inflammation has been found to be associated with prostatic enlargement, severity 32 
of LUTS and symptomatic progression. That is the focus of this review. 33 
    34 
Prostate inflammation: Prostatic inflammation is evident by inflammatory cells infiltrating the prostatic 35 
stroma, epithelium, and/or prostate glands (Cotran RS et al, 1999; Nickel et al., 2008). Acute and 36 
chronic inflammation has been identified in 40-50% of prostatic samples obtained by biopsy, surgery, or 37 
autopsy (Delongchamps et al., 2008; Kohnen and Drach, 1979; Theyer et al., 1992; Steiner et al., 1994; 38 
Kramer et al., 2006; Di Silverio, et al., 2003). Chronic inflammation is more common than acute 39 
inflammation (78% versus 15%, respectively; Moreira et al., 2014).The etiology of prostatic 40 
inflammation is likely multi-factorial. Urine refluxes freely into the prostatic ducts (Kirby, 1982) and 41 
provides a route for bacterial colonization. (Weiss, 1983; Krieger and Riley, 2002). Other potential 42 
causes include viruses, dietary components, changes in serum testosterone and estrogen levels, 43 
autoimmune mechanisms, and reflux of noxious chemicals in the urine (DeMarzo et al., 2007; 44 
Gandaglia et al., 2013).  In addition, prostate inflammation can be triggered by metabolic alterations 45 
including metabolic syndrome and dyslipidemia (Vignozzi et al 2016; DeNunzio et al 2012; Freeman 46 
and Solomon 2011). All told, these studies point to a systemic and metabolic cause for prostatic 47 
inflammation. 48 
 49 
Inflammation is more common in men with BPH/LUTS and correlates with symptom severity and 50 
risk for progression. In a prospective study of autopsy specimens obtained from 93 men with 51 
histological evidence of BPH, chronic inflammation was found (primarily in the transitional zone) in 75% 52 
of prostates examined compared to 55% of prostates not affected by BPH (Delongchamps 2008). 53 
Evidence of inflammation on baseline biopsy in the Medical Therapy of Prostate Symptoms (MTOPS) 54 
trial correlated with prostate volume (41 vs 37 cc; p=0.0002) and greater risk for symptomatic 55 
progression, urinary retention and need for surgery (Roehrborn, 2006).  It has been postulated that 56 
inflammation may contribute to prostate enlargement by inducing hyperplasia. However, it has also 57 
been postulated that prostatic inflammation could cause urinary frequency and urgency by directly 58 
influencing bladder sensation and detrusor function (Geppetti, 2008).   Pelvic organs share innervation 59 
and it has been shown that inflammation of one pelvic organ can produce cross-sensitization of other 60 
pelvic viscera (Qin, 2005; Rudick, 2007; Ustinova, 2007; Ustinova, 2006). This has been postulated to 61 
occur, in part, by triggering activation of afferent sensory nerves (Candenas, 2005; Lecci, 2001; Maggi, 62 
1997). Recently we showed that isolated prostate inflammation in the laboratory mouse produces a 63 
significant increase in voiding frequency (Lee et al., 2015).  The anatomic basis for this may be 64 
convergent innvervation of the bladder and prostate: afferent neurons in the lumbosacral dorsal root 65 
ganglia providing afferent innervation of the both the prostate and bladder (manuscript submitted). 66 
These observations resonate with the selective correlation of inflammation with irritative LUTS in the 67 
REDUCE trial (Nickel et al., 2008). 68 
 69 
Prostatic fibrosis and bladder outlet obstruction: While prostatic enlargement correlates with 70 
increased urethral resistance and LUTS (Bushman, 2009), many men experience bladder outlet 71 
obstruction and symptoms in the absence of significant prostatic enlargement (Blaivas, 1996; 72 
Bushman, 2009). Increased adrenergic tone of smooth muscle in the prostate may be a contributing 73 
factor, but the frequent ineffectiveness of medical therapy with alpha-blockers argues for additional 74 
mechanisms. It has been speculated that fibrosis of the prostate may increase urethral restance and 75 
several studies have provided evidence for periurethral firbrosis,. decreased elastin  and changes in 76 
tissue compliance  (Bercovich et al., 1999; Diavan et al. 1999; Morrison et al., 2000; Ma et al., 2012; 77 
Rodriguez-Nieves and Macoska 2013; Cantiello et al. 2013; Bauman et al. (2014).  The etiology of 78 
prostate fibrosis is uncertain but chronic inflammation is an obvious candidate.  Studies in the mouse 79 
have shown that prostate inflammation does induce an increase in collagen content (Wong et al., 80 
2014a) and there is a suggestion in human studies of a correlation between inflammation and fibrosis 81 
(Cantiello et al., 2013).   82 
 83 
Cells and mechanisms. The majority of infiltrating leukocytes in the inflamed human prostate are 84 
chronically-activated T lymphocytes and macrophages (Theyer et al. 1992; Steiner et al. 2003). Mouse 85 
models of inflammation exhibit very similar infiltrative components as inflamed human prostates 86 
(Boehm et al 2012; Haverkamp et al 2011). Th1 cells regulate the immune response to intracellular 87 
pathogens via IFN and IL-2. Th2 cells produce IL-4, IL-13 and IL-5 and regulate the hypersensitivity 88 
response. Th17 cells are responsible for host defense against extracellular pathogens (Rautajoki et al. 89 
2008) through IL-17 and IL-21. Resident epithelial and stromal cells express several toll-like receptors 90 
including TLR-4, TLR-5, TLR-7 and TLR-9, and also produce IL-1, IL-6, and IL-15 during inflammation 91 
(Kramer & Marberger 2006). Prostatic epithelial cells express class II MHC molecules that participate in 92 
organ-specific inflammation (Penna et al. 2009), resulting in the production of IL-6, IL-8 and CXCL10 93 
and leukocyte recruitment (Penna et al. 2009). Stromal cells express CD80, CD86, CD40, and CD134L 94 
(Penna et al.2009) and   activate T lymphocytes directly. These activities contribute to a chronic state of 95 
inflammation.   96 
 97 
The cytokines and growth factors highly expressed in BPH include IL-1, IL-6, IL-8, IL-15, IL-17, IFNγ, 98 
TGFβ, FGF2 and 7, and IGF-1 (Handisurya et al 2001; Steiner et al 2003; Hahn et al. 2014; Giri and 99 
Ittman 2001). These cytokines have been proposed as a link between chronic prostate inflammation 100 
and prostatic hyperplasia because they intersect with critical stromal and epithelial paracrine signaling 101 
pathways that regulate prostate growth. The Jak-STAT signaling pathway is induced by a number of 102 
these cytokines, most notably IL-6 and IL-1 (Shankar et al 2014; Jerde and Bushman 2009; Verma et al 103 
2014). The NFκB signaling pathway is a major player in inflammatory signaling (Bouraoui et al 2012) 104 
and is induced by IL-1 downstream of MyD88. Interesting, androgen receptor signaling also results in 105 
activation of this pathway (Atawia et al 2014). Interesting, androgens have also been shown to play a 106 
critical role as anti-inflammatory agents, as men on anti-androgen therapy develop prostatic 107 
inflammation; this has been corroborated in mouse models (Izumi et al 2014). Phosphoinositide 108 
signaling is the major pathway downstream of IGF-1 and is highly activated in the epithelium of BPH 109 
and inflamed prostates (Hahn et al 2014). Secreted ligands of G-protein-coupled receptors (GPCRs) 110 
including prostaglandins, epinephrine, acetylcholine, histamine, and kinins activate pathways that 111 
include PKCs, cAMP, nitric oxide (NO), and phosphodiesterases (PDEs) during prostatic inflammation.   112 
 113 
Opportunities for improving care.  Recent studies of BPH/LUTS strongly suggest it to be a complex 114 
symptomatic condition with a multifactorial etiology. Improvements in diagnosis and treatment of 115 
BPH/LUTS will hinge upon finding methods to sub-classify patients according to etiology and to select 116 
the most efficacious treatment.  In this regard it is notable that there is evidence suggesting that 117 
patients with high-grade prostate inflammation are less likely to respond to standard medical therapy 118 
(Kwon et al., 2010).  If this is true, then non-invasive biomarkers of inflammation would be useful to 119 
identify patients likely to respond to medical therapy and at greater risk for symptomatic progression 120 
and urinary retention. Greer et al. (2015) used liquid chromatography mass spectrometry to compare 121 
over 800 proteins in BPH/LUTS patients and controls. Gene ontology (GO) analysis of the 50 122 
differentially expressed proteins proteins showed revealed many were involved in inflammatory 123 
responses and implicated in fibrosis. Additionally, targeting the noted metabolic alterations associated 124 
with BPH-LUTS (Vignozzi et al 2016) could have the systemic effect of reducing prostatic inflammation 125 
in patients with LUTS, and therefore could have a beneficial impact on LUTS severity and progression. 126 
 127 
Novel therapeutic targets involving inflammatory signaling. A recent comprehensive review and 128 
meta-analysis by Kahokehr and associates demonstrates that there is a therapeutic benefit to treating 129 
BPH with anti-inflammatories (Kahokehr et al 2013). Additionally, the specific COX-2 inhibitor celecoxib 130 
has been shown to reduce BPH symptomology (Falahatkar et al 2008). This provides proof-of-principle 131 
for efficacy or therapeutically targeting prostate inflammation and impels the search for therapies to 132 
target inflammatory pathways in BPH. 133 
 134 
The new awareness of inflammation’s role in BPH has led to speculation that established medical 135 
therapies for BPH may be related to secondary anti-inflammatory effects. [Table 1.] Alpha-adrenergic 136 
antagonists are generally considered to act by relaxing the smooth muscle of the bladder neck and 137 
prostate but could more generally block the actions of epinephrine induced during prostatic 138 
inflammation.  The 5-alpha-reductase inhibitor finasteride interferes with androgen action in the 139 
prostate, but it also has anti-nociceptive and anti-inflammatory actions (Duborija-Kovacevic et al. 2008). 140 
The phosphodiesterase type-5 (PDE5) inhibitor tadalafil has been approved for treatment of BPH-141 
LUTS. PDE5 inhibitors increase nitric oxide synthase (NOS) and NO activity, inactivate cGMP-142 
mediated ρ-kinase, and decrease of autonomic hyperactivity in the bladder (Kang et al. 2007). 143 
However, PDE activity is induced during inflammation and part of the efficacy of PDE5 inhibitors could 144 
be due to anti-inflammatory effects. Indeed, a recent study showed PDE5 inhibitors have substantial 145 
anti-inflammatory activity in the prostate (Vignozzi et al, 2013; Peixoto et al. 2015). The role of 146 
histamine in neurogenic inflammation is well-established (Rosa and Fantozzi, 2013), and given the 147 
strong neuronal component to prostatic inflammation, it is possible that histamine antagonism may be 148 
effective as anti-inflammatories in the prostate. Similarly, tachykinins and calcitonin gene-related 149 
peptide (CGRP) are neuropeptides present in the prostate, and are highly produced during neurogenic 150 
inflammation. Both are involved in prostatic and bladder smooth muscle contraction (Buljubasich et 151 
al.1999; Ventura et al., 2000). Similar to the sensory neuropeptides, endothelins are neurogenic 152 
inflammation-produced peptides involved in nerve-mediated contractions (Lau et al. 1999), and 153 
blockade of ET receptors circumvents inflammation-induced contraction as well as proliferation of 154 
resident cells (Saita et al. 1998) 155 
 156 
Fibrosis as a target of prevention or treatment. Recent evidence suggesting prostatic fibrosis plays 157 
a central role in the development of bladder outlet obstruction in aging men begs the question – can 158 
fibrosis be prevented or reversed? Efforts to prevent fibrosis will depend on identifying the actual 159 
etiologies and natural history of changes in prostate collagen and elastin content. This is a fertile area 160 
for investigation.  We have shown that fibrosis of the mouse prostate induced by inflammation of limited 161 
duration is partially reversible (Wong et al., 2014b), however, the reversibility of fibrosis in the human 162 
prostate has not been examined. Clearly, proving the associations of inflammation, fibrosis and bladder 163 
outlet obstruction and then development of medical or minimally invasive therapies to both prevent and 164 
reverse prostate fibrosis will be a research priority.  165 
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Figure 1. (DeMarzo et al. 2008) Prostatic inflammation has numerous potential causes, including 
infectious agents, dietary habits, hormonal changes, and physical trauma and urinary reflux. 
Drug Class Proposed Mechanism Examples Current Status 
Alpha-adrenergic 
antagonists 1. Smooth muscle relaxation Alfuzosni Approved  
  2. Anti-nociceptive Prazosin First Line Therapy 
  3. Anti-inflammatory-uncertain mechanism Doxazosin   
    Tamsulosin   
    Terazosin   
5-alpha reductase 
inhibitors 1. Blockade of DHT synthesis from T Finasteride Approved  
  2. Anti-inflammatory-uncertain mechanism Dutasteride   
NSAIDs Blockade of prostaglandin synthesis Naproxen Approved, OTC 
    Ibuprofen Often suggested by 
    Celecoxib Physician 
Phosphodiesterase 5 
inhibitors Inhibition of Type 5 PDE isoform sildenafil Approved 
  1. Smooth muscle relaxation tadalafil   
  2. Blockade of leukocyte infiltration     
Purinoceptor 
antagonists Blockade of P2X1-purinoceptors   In development 
Anti-histamine Anti-inflammatory action at H1 receptors Numerous OTC Approved, OTC 
      Often suggested  
Endothelin 
antagonists Blockade of inflammatory infiltrate at ET receptors Ambrisentan Off label  
    Atrasentan Approved for cancer 
    Bosentan   
Rho Kinase inhibition Blockade of inflammatory infiltrate by small GTPase inhibition   In development 
 343 
Table 1: A summary of current pharmacological therapies for BPH targeting components of inflammation or 344 
inflammatory signaling. 345 
 346 

